Whole genome sequencing of matched primary and metastatic acral melanomas
Samra Turajlic(Royal Marsden NHS Foundation Trust), Richard Marais(Macclesfield College), Iwanka Kozarewa(AstraZeneca (United Kingdom)), Gordon Stamp(Royal Marsden Hospital), Simon J. Furney(King's College London), Alan Ashworth(University of California, San Francisco), Costas Mitsopoulos(Institute of Cancer Research), Alan Mackay(Institute of Cancer Research), James Larkin(Trinity College Dublin), Jorge S. Reis‐Filho(AstraZeneca (France)), Christopher J. Lord(Institute of Cancer Research), Felipe C. Geyer(Institute of Cancer Research), Meirion Thomas(Royal Marsden Hospital), Jarle Hakas(Institute of Cancer Research), Maryou Lambros(Institute of Cancer Research), Marketa Zvelebil(Institute of Cancer Research)
Cited by 169
Related Papers
Mutations of the BRAF gene in human cancer
|Nature|2002|10.7k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k